.png){kind=logo}
™
Unlocking first-in-class biologics with genetics-inspired functional screening at scale.
.png)
About Us
The future of biologics starts here
Founded in 2016 and incorporated in 2019, Heligenics Inc. is transforming biologic drug discovery through our proprietary GigaAssay™ technology.
The GigaAssay is the first and only high-content screening platform for biologics.
"Heli" is derived from “hÇ£lan” an old English word that means “to heal” and “genics” which stands for genomics. Heligenics is a biotechnology company dedicated to accelerating and de-risking biologics discovery by delivering unprecedented functional insights at massive scale. Our expertise lies in the high-throughput assay of biologic drug candidates, offering rich, actionable data on molecule performance in human cellular environments, enabling faster and smarter decisions in drug development.
Our Unique Advantage
Unlike traditional low-throughput methods, Heligenics delivers:
-
High-content, high-throughput functional screening of biologics.
-
Direct measurement of functional activity across hundreds of thousands of variants in human cells.
-
Hypothesis-free discovery of best-in-class therapeutic candidates.
-
Data-driven optimization for potency, immunogenicity, safety, resistance, and efficacy.
​Our partnerships and services focus on building comprehensive variant libraries of biologic drug candidates including every variant within a therapeutic gene or molecule and testing them using custom cell-based GigaAssays. This approach provides direct, high-resolution and high accuracy functional readouts that drive the identification and optimization of high-potency drug leads, dual-agonist biologics, and multi-specific therapeutics.
​
Heligenics is pioneering a fully comprehensive, discovery approach, analogous to genome-wide association studies — but for functional biologics. This enables our customers to:
-
Rapidly discover and optimize first-in-class and best-in-class biologics.
-
Select the most promising candidates earlier in development.
-
Rescue stalled clinical programs with deeper functional insights.
-
Expand the addressable market through mechanism-informed design.
​
Our exclusive GigaAssay technology unlocks a paradigm shift in biologics discovery — moving beyond guesswork and low-throughput screening to a scalable, data-driven process that delivers better molecules, faster.
​
With the GigaAssay, you gain the clearest functional map (see structure representation below) of your molecules or target — innovation that drives discovery of best-in-class biologics. Accelerate drug development, rescue stalled programs and identify first-in-class therapeutics with the GigaAssay.
​
​
​
​
​
​
​
​
​
Our technology supports:
-
Rapidly select lead candidates.
-
Functionally characterize multi-specific biologics and dual agonists.
-
Optimize biologics for efficacy, safety, immunogenicity, and stability.
-
Rescue and repurposing of biologics with functional clarity.
-
Drive data-first discovery pipelines with comprehensive functional datasets.
At Heligenics, we are committed to revolutionizing biologics R&D, delivering higher success rates, faster timelines, and transformational therapeutics to market.
​
Contact us today to find out how Heligenics can revolutionize your biologics discovery!
Unlock structure-activity insights on your lead candidates
.png)